Developments in China’s biotechnology sector, from research breakthroughs and diagnostics to industrial biotech and manufacturing.
The influx signals a strategic pivot, as Beijing funnels its most promising private innovators—particularly in biotech and AI—toward Hong Kong’s deep capital markets, reshaping the global funding landscape for life…
A Chinese diagnostic firm’s plan to expand in Hong Kong signals how pandemic-era public health partnerships can become a launchpad for long-term commercial strategy in one of Asia’s most competitive…
For global pharmaceutical professionals, the prospect of a Chinese company successfully navigating US biological drug approval for the first time signals a shift in competitive dynamics that extends well beyond…
A profitable Hong Kong-based biotechnology company is moving toward a public listing to finance the development of treatments for Alzheimer’s and other neurological diseases, a sign that China’s biotech ambitions…
For global biotech and life sciences firms weighing an IPO in Asia, Hong Kong’s willingness to rewrite its listing rules signals a serious effort to draw capital and talent away…
As the global race for a Covid-19 cure accelerates, China’s biotechnology sector is experiencing a powerful wave of consolidation and capital inflows, signalling a strategic shift in the country’s pharmaceutical…
For global pharmaceutical and tech investors, the convergence of deep-pocketed AI giants and drug discovery marks a pivotal shift in how new therapies may be developed. In a move that…
For global pharmaceutical executives and investors, the coming wave of consolidation in China’s outsourced drug discovery sector signals an urgent window for strategic positioning in the world’s second-largest pharma market.…
For global pharmaceutical executives and investors tracking China’s ascent in innovative drug development, the scale of Chi-Med’s planned commercial buildout signals confidence not just in its pipeline, but in the…
For global professionals tracking China’s biotech trajectory, the Hong Kong-Singapore comparison is a revealing lens on how policy, infrastructure, and regional integration shape a sector’s fate. The Greater Bay Area…
No products in the cart.
